.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The MANAS 1 AI model represents a significant leap in Indian neuroscience and medical technology. Developed by Intellihealth and led by Dr. Puneet Agarwal, this foundational platform interprets complex electrical signals from the brain. By analyzing 60,000 hours of EEG recordings, the system aims to identify neurological conditions before they become visible on traditional scans. This breakthrough could transform how clinicians approach early diagnosis for millions of patients.
Traditional diagnostic tools like MRI often fail to capture the real-time electrical nuances of brain function. Consequently, doctors must rely on visible structural changes which appear late in disease progression. The MANAS 1 AI model addresses this gap by training on data from over 25,000 patients. It features 400 million parameters designed to understand the \"basic language\" of the brain. Because it is an open-source tool, researchers can now build specialized applications for epilepsy and dementia upon this core architecture.
India currently faces a significant shortage of neurologists and psychiatrists, especially in rural areas. Therefore, late detection of brain disorders remains a major public health challenge. Since the model provides a scalable screening tool, it could empower doctors at community health centers to perform preliminary assessments. Early intervention usually reduces long-term disability and healthcare costs for families. Furthermore, the upcoming release of MANAS 2 suggests that this technology will continue to evolve rapidly.
Q1: What makes MANAS 1 different from conventional medical AI?
Unlike standard systems that analyze text or images, MANAS 1 is specifically trained to interpret EEG signals, which are the raw electrical activities of the brain. It acts as a foundational platform rather than a single-purpose tool.
Q2: Can this model be used in clinical practice immediately?
While the model is available for research on Hugging Face, any specific diagnostic tool derived from MANAS 1 requires regulatory approvals before clinicians can use it for patient care.
Q3: Which disorders can MANAS 1 help detect?
The platform is designed to support the development of tools for detecting epilepsy, dementia, and various other psychiatric and neurological conditions by decoding brainwave patterns.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
India launches MANAS 1, an open-source AI trained on 60,000 hours of EEG data to enable early detection of neurological and psychiatric disorders....
6 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
